Introduction
Nausea and vomiting are well recognized in many diverse clinical situations, suggesting that no single mechanism is likely to be responsible for their production. Cytotoxic drugs, used in the treatment of a range of malignancies, may produce severe gastrointestinal toxicity. This may lead to a refusal of curative therapy or to a decline in palliative benefits offered by cytotoxic treatment. The exact mechanisms of chemotherapy induced nausea and emesis are poorly understood; however, an appreciation of the vomiting process remains essential to a rational approach to the therapeutics of anti-emesis.
The chemoreceptor trigger zone and the area postrema Having described and localized a medullary vomiting centre (MVC), Borrison and Wang postulated the existence of a separate chemoreceptor trigger zone (CTl), sensitive to emetic agents such as apomorphine, morphine, cardiac glycosides, nicotine, t-dopa and a variety of cytotoxic agents'. The CTZ was then associated with the area postrema (AP), a spongiform vascular body protruding into the lumen of the fourth ventricle. The blood vessels supplying the AP are derived mainly from the posterior inferior cerebellar, posterior spinal and vertebral arteries and consist mainly of sinusoidal capillaries, which permit systemically injected dyes to leak through into the underlying tissue. The AP also exchanges solutes directly with cerebrospinal fluid (CSF), by means offree flow through pericapillary spaces, which are continuous with the subarachnoid fluid space". The exact significance of this blood-brain interface remains uncertain. It has been suggested that a countercurrent mechanism may operate in the AP. Such a system would be useful for concentrating blood borne toxins, in that very low levels would be detectable by the AP. This would be consistent with a function of monitoring and sampling emetic agents".
To test the hypothesis that circulating emetic substancesI'activate neurons in the AP, Carpenter et al. (1984) demonstrated the response in the AP of anaesthetized dogs to 17 common transmitters and peptidea". Excitatory responses were found to histamine, noradrenaline, serotonin, dopamine, apomorphine, angiotensin II, neurotensin, leucine enkephalin, VIP, thyrotropin releasing hormone, gastrin, vasopressin and substance P. Because of the positive response of such a large number of substances, the authors suggested that a common mechanism for emesis was likely, namely a species of ionic channel coupled to each receptor type or a common second messenger. It was also noted that the emetic response of the animal to these substances was dependent on the integrity of the AP.
Neuronal connections of the AP The AP receives a significant visceral afferent input by way of the vagal nerve which includes sensory information from the thoracic and abdominal viscera. The glossopharyngeal nerve also projects to the AP to provide baroreceptive information via its carotid sinus component. The two main outputs of the AP seem to be to the nucleus tractus solitarious (NTS) and to the parabranchial region. The important reciprocal connections of the AP with the NTS and its dorsomedial region, the subnucleus gelatinosus (SNG), seem likely to be a means of indirect afferent and efferent pathways from the AP to the dorsal vagal motor nucleus in the medulla".
Neurochemistry of the AP Studies suggest the presence of cholinergic, GABAergie, histaminergicflf.), opiate and catecholaminergic receptors in the human AP. In rats, catacholaminergic neurons receive direct synaptic input from serotonergic and vagal sensory afferents, and co-localization of opiate peptides and serotonergic neurons may suggest that the opiate peptides and 5HT serve the same or possibly interrelated functions in certain neurons", Neurotransmission within the AP suggests a basis on which combination therapeutic regimens can be based.
Other functions of the AP The AP has some influence over cardiovascular effects of angiotension; serotonin induced electroencephalographic arousal; salt and water excretion; bloodglucose regulation; conditioned taste aversion; defaecation; inhibition of rumination; gastric secretion and motility and regulation of the sleep cycle. However, ablation of the AP results in no gross behavioural defects. This may suggest that the AP carries out limited control over the various functions, acting perhaps as a 'fine tuning' mechaniaml-U.
The medullary vomiting centre In 1949 Borison and Wang localized the responsive locus for vomiting to the dorsolateral border of the lateral reticular formation and suggested that at least part of the responsive region of emesis was the vomiting centre". Miller and Wilson (1983) failed to reproduce these experiments and concluded that a discretely localized vomiting centre did not exist 9 • This failure of reproducibility has led current thinking to favour the concept that neurons subserving some component of the vomiting phenomenon, when stimulated appropriately, act in an integrated way to produce the vomiting process. The model for this process has been suggested recently to be one of 'sequential activation' as opposed to the parallel activation model formerly accepted. This sequential theory acknowledges the existence of a threshold for the initiation of the vomiting process and might then help explain why some epiphenomena of vomiting may be activated without triggering actual expulsion of vomitus. It would also help explain various time lags before the onset of vomiting in that the vomiting act would be a 'summation of the spatial linkages between the discrete effector nuclei'. This presumably means that sufficient neurochemical input must be achieved before vomiting is initiated, thus preventing accidental expulsion of vomitus'', Peripheral pathways involved in the vomiting process Peripheral inputs to the vomiting centre are important components of the afferent arm of the vomiting process. The afferent signals from the periphery are conveyed via the vagal and splanchic nerves. Work in ferrets demonstrated retching and prodromata of vomiting on stimulation of the vagal nerve and that vomiting, due to distension of the pyloric pouches of nitrogen mustard in the stomach, can be abolished by vagotomy. Vomiting due to oral copper sulphate administration, however, requires intact vagal and splanchic afferents. Despite projections from the vagal afferents to the AP, stimulation of these nerves can cause vomiting without AP integrity, demonstrating that vagal afferent stimulation affects the MVC directly'P,
The study of efferent pathways from the vomiting centre to the GI tract which bring about gastric relaxation and anti-peristalsis suggests that prodromal gastric relaxation is brought about by preganglionic vagal output which innervates intrinsic inhibitory neurons in the gastric wall!'.
Cytotoxic induced nausea and vomiting
Chemotherapy induced vomiting is thought to act via the CTZ/AP. Evidence for this is shown by experimental ablation of the AP to eliminate the emetic response to known emetic stimuli. This has been shown for cisplatinum induced emesis in cats 12 • From the area postrema the efferent pathways to the vomiting centre in the medulla pass via the NTS which itself may act as a collator and perhaps modifier of various different inputs. Borison and McCarthy13 describe a system in which input data from various sources is relayed by specific neurotransmitter release to the vomiting centre. Here the afferent signals would be integrated and efferent impulses transmitted via a minimum of three neurotransmitter pathways initiating nausea, retching and expulsion. Such a system would theoretically allow blockade of the cytotoxic stimulus at the chemosensory level, at its transmission between AP and vomiting centre and at the efferent end of the circuit 13 • Despite the identification of several important neurotransmitters, no single anti-emetic agent has been able to counteract chemotherapy induced emesis with universal success. This suggests that complexpatterns ofchemoreception and neurotransmission are occurring within the APtractus solitarius-vomiting centre axis.
In experimental and clinical situations it has been noted that there is frequently a delay between the emetic stimulus and the emetic response. This is seen to varying degrees with different cytotoxic agents and is suggestive of an indirect rather than direct mechanism of action in either or both the CTZ and the medullary reticular formation. How this occurs Journal of the Royal Society of Medicine Volume 81 November 1988 659 is uncertain, but theoretically, release of some intermediate factor could account for a slow build-up of substance to threshold levels and subsequent production of emesis. It has been suggested that such an intermediatory role may be undertaken by endogenous opiates-v, Workers studying the enkephalin receptors in the CTZ of the dog administered met-enkephalin into the fourth ventricle and produced emesis with a very short latency at 35-40 seconds. This may suggest that the stimulus to emesis has preempted several steps in the transmission pathway by directly increasing a potentially important intermediatory, but this is conjecture, The importance of the CTZ in the recognition of this peptide was underlined by ablation of the CTZ. In these CTZ ablated animals, five times the 100% emetic dose of met-enkephalin failed to produce emesis. Furthermore, small doses of naloxone successfully prevented emesis in the intact animals treated with met-enkephalin. From this it appears that there are specific opiate receptors in the CTZ, sensitive to naloxone blockade and when stimulated, capable of inducing vomiting 14 • The same workers using the exact experimental model, also showed the emetic effect of morphine and apomorphine. Pretreatment with naloxone, only afforded protection against morphine induced vomiting suggesting that although the CTZ is the site of action for both morphine and apomorphine, different receptors exist for the two drugs. The authors postulate that morphine acts via the enkephalin receptors in the CTZ and that apomorphine may act via the dopaminergic pathways.
Previous work on narcotic induced emesis and antiemesis had also demonstrated that the narcotic receptor specificity of the CTZ did not encompass the emetic action of apcmorphine-s. It suggested the existence of an anti-emetic tone mediated through endogenous morphine-like factors. The site proposed for such an action was an 'anti-emetic' centre in the medullary reticular formation, as morphine was found to continue to exert its anti-emetic effect in cats with the CTZ ablated. The different patterns of emetic and anti-emetic effect seen between morphine and other narcotics was explained in terms of lipid solubility. Thus ifa narcotic reaches the anti-emetic site of action faster than emesis can develop, no vomiting should result. More recently it has been suggested that different types of opiate receptor were responsible for emetic and anti-emetic effects of the narcotics. Naloxone is much less effective at inhibiting binding of enkephalins and opiates to delta receptors than at mu receptors10.
Given this data, the hypothesis on enkephalin mediated pathways can be appreciated. Cytotoxic drugs are thought to produce their emetic effects by inhibition of rapidly turning over enzyme systems, responsible for the breakdown of neurotransmitter substaneeal''. This inhibition would result in an increase in neurotransmitter levels, specifically enkephalins, which would then mediate the production of emesis probably via opiate receptors in the CTZ. This helps account for the time lag observed between the administration of cytotoxic drugs and the onset of vomiting. Different agents inhibit enzymes at different points in their synthetic pathways and consequently at different speeds, hence the rapid onset of emesis with cisplatinum, an enzyme inhibitor via heavy metal toxicity10.
Cytotoxic drugs crossing the blood-brain barrier may inhibit enkephalin production at the 'anti-emetic' centre so decreasing the endogenous anti-emetic tone. It is suggested that this would potentiate effects mediated via the AP. However, if enkephalins are the vital link between the cytotoxic stimulus and the vomiting process, conclusive evidence would need to demonstrate an increase in enkephalin levels in the CTZ and a concomitant decrease in enkephalinase activity during chemotherapy induced vomiting. In addition it would be useful to measure the levels of these peptides within the CSF.
Anticipatory nausea and vomiting
In addition to post-treatment emesis, many patients experience anticipatory nausea and vomiting (ANV) usually after several courses of chemotherapy. ANV is pretreatment emesis. The more severe the posttreatment nausea and vomiting, the more likely a patient is to develop ANV. Anticipatory nausea has been reported at 18.3-44.4%and anticipatory vomiting at 9-38%. Younger patients showed a significantly higher incidence of ANV than an older age group. ANV is also thought to be associated with frequency and length of treatment and disease status. Precipitating factors seem to be related to taste-smell aversions, to the drugs themselves and to anxiety states about the chemotherapy. The phenomenon is probably a manifestation of a classical Pavlovian conditioning and stresses the importance of the input from the limbic system and higher centres", General mechanisms of action of anti-emetic drugs The most commonly used anti-emetics are those which block dopamine, histamine or acetylcholine receptors and selective receptor antagonism has formed the basis of the approach to anti-emetic therapeutics. More recently, newer drugs have been introduced either as single agents or in combination regimens and their actions are more likely to be explained by other mechanisms or other receptor interactions.
If the anti-emetic centre in the medulla is important in the control of the vomiting process then steroids will decrease the access of drugs to the anti-emetic centre by effects on the blood-brain barrier. Alternatively steroids could have their anti-emetic effects by reducing prostaglandin release by glial cells.
The cannabinoids do not inhibit dopamine, histamine or cholinergic receptors. Nabilone may act on opiate type receptors in the forebrain and this in turn may result in inhibition of the vomiting centre via descending connections!", It is also possible that nabilone may bind to the mu receptors in the medullary reticular formation. Stimulation of the mu receptors leads to enkephalin release and 80 promotes the maintenance of the anti-emetic tone 10.
Evaluation of specific anti-emetics
Prochlorperazine Prochlorperazine is a dopamine antagonist which is active at both D, and D 2 receptors. Like other phenothiazines it has antihistaminergic (HI) anticholinergic and antiadrenergic (alphal) properties but it is uncertain whether these contribute to its therapeutic effect 18 • Prochlorperazine has been evaluated in over 27 trials. The early trials reported the superiority of prochlorperazine over placebo, several other phenothiazines and benzquinamide-", but the drug has been superceded by high dose metoclopramide with the advent of more emetogenic chemotherapy regimens.
Metoclopramide
Metoclopramide is a procainamide derivative with peripheral and central dopamine antagonist activity. It shows selectivity for D 2 receptors. It also has cholinomimetic actions in the gastrointestinal tract by influencing the release of acetylcholine possibly via antagonism at presynaptic cholinergic receptors. Metoclopramide is also thought to possess antiserotonergic propertiesl'', Metoclopramide's effectiveness seems to be dose related and high dose metoclopramide was shown to be superior to placebo prochlorperazine or cannabinoids. A comparison between single IV metoclopramide and dexamethasone in cisplatinum treated patients showed metoclopramide to be superior to dexamethasone in the prevention of nausea and vomiting.
Domperidone
Domperidone is a benzimidazole derivative which is a peripheral dopamine receptor blocker promoting gastric motility. It is thought to offer advantages over conventional anti-emetics since it does not cross the blood-brain barrier and therefore produces a low incidence of CNS side effects including sedation and extrapyramidal reactions. Domperidone, like metoclopramide also acts at the CTZ, D 2 blockade.
Domperidone has been shown to be superior to placebo and either superior or equivalent to metoclopramide'Pr",
Butyrophenones
Both droperidol and haloperidol are dopamine antagonists thought to exert their effect via the CTZ. Haloperidol has been shown to be superior to benzquinamide. Droperidol proved to be superior to prochlorperazine. Both butyrophenones have a considerable sedatory effect 2o •
Steroids
Dexamethasone is widely used both as a single agent and in combination with other anti-emetics. As a single agent it is superior to placebo and prochlorperasine'", but in combination with high dose metoclopramide it may be superior to metoclopramide alone.
The lack of side effects with dexamethasone and its promotion of well-being has been demonstrated by patient preference for the drug even when no statistical superiority can be shown for the regimen which includes dexamethasone.
Cannabinoids
Three such drugs have been evaluated, delta 9 tetrahydrocannabinol (THC), nabilone and levonantrodol. Trials involving patients treated with highly emetogenic regimens showed THC to be equal or superior in activity to prochlorperazine and haloperidol but inferior to high dose metoclopramide. However, because of side effects with THC, patient preference was in favour of the less effective drugs'", Nabilone, a synthetic cannabinoid, produces less side effects than THC. Studies have shown its superiority to placebo and prochlorperazine and low dose metoclopramide. Nabilone showed equal effectiveness with chlorpromazine but patient preference was for nabilone'".
The newest cannabinoid is levonantrodol. Evidence suggests unacceptable toxicity with this drug, despite good anti-emetic properties.
5HT receptor antagonists
Recently work on the use of 5HT antagonist drugs has suggested a therapeutic role for selective 5HT3 receptor blockade. It has been postulated that the effectiveness of high dose metoclopramide may be due to a 5HT 3 antagonism in the afferent arm of the emetic pathway. Work in ferrets using specific 5HT 3 antagonism has shown that a 5HT 3 antagonist can block cisplatinum induced emesis 22 • From this it is suggested that 5HT should be considered as a possible neurotransmitter involved in cisplatinum induced emesis, particularly since large numbers of 5HT containing neurons can be found within the area postrema. It is suggested that the afferent arm of the emetic circuit in which 5HT3 receptors exist, when activated could provoke emesis via 5HT neuronal input into the CTZ. CTZ ablation would eliminate such a mechanism and so relieve emesis 22 • In a recent study, 14 patients being treated with cisplatinum received a 5HT3 receptor antagonist (dose 40 JLg/kg). Eight had complete absence of gastrointestinal toxicity and the remaining 6 had significant improvement in the degree of nausea and vomitingf", Alternative methods of anti-emesis Recently, acupuncture has been highlighted as a means of reducing emesis. Workers in Belfast have shown that acupuncture is successful in the treatment of perioperative nausea and vomiting. A similar procedure offeredto patients undergoing chemotherapy also proved beneflcial'", Future research: vasopressin and {j-endorpbine release during nausea and emesis In standard emetic doses, the dopamine agonist apomorphine has been shown to produce nausea and vomiting and massive increases in plasma arginine vasopressin (AVP). Smaller doses of apomorphine which produced nausea but no vomiting, also consistently provoked large increases in plasma AVP. This appeared to occur independently of any known AVP stimulus'", A recent study of plasma AVP levels in patients receiving chemotherapy has demonstrated significant rises, from basal levels, of plasma AVP in those patients who vomited during treatment. No such rises were seen in patients who did not vomit <Edwardset al., 1988 submitted for publication). In this instance, AVP may be acting as a marker for emesis (a biochemical assessor of emetic status) or may form a part of a sequential mechanism for chemotherapy induced vomiting. The role of {j·endorphine in such a mechanism has also been supported by a study in which only patients suffering from cytotoxic drug induced nausea and vomiting showed increased levels of plasma {j.endorphine 26 • 
Discussion
Despite all that is known about the factors involved in chemotherapy induced vomiting, no definite statement can be made on its exact mechanism. The failure to identify a specific neurotransmitter controlling Journal of the Royal Society of Medicine Volume 81 November 1988 661 either the afferent or efferent arm of the vomiting pathway and the uncertainty about the interrelationship of the various components of the system leads us to base anti-emetic regimens on pharmacological antagonism of any likely transmitter candidates.
The CTZ/AP axis is an attractive model for the production of cytotoxic induced emesis, especially when coupled with the hypothesis of intermediatory pathways; however, the importance of peripheral contributions to such a system should not be overlooked. The presence of neuropeptides both in the gut and the CNS could well be suggestive of some functional link. Peripheral release of these compounds in response to an emetic stimulus may prove an important step in the emetic pathway, the released peptides then acting via the CTZ to provoke emesis. Carpenter's work. has already demonstrated the potential of such substances to provoke excitation in AP neurons. This being the case it would be useful to measure levels of these peptides in peripheral blood during cytotoxic administration. Ideally some measure of CSF levels of these peptides would also be obtained, at the same time.
An alternative line of approach would be to attempt to enhance the endogenous anti-emetic tone. This might be achieved by the administration of an opiate analogue in low doses. An analogue with a high lipid solubility would be desirable in order to promote the levels of endogenous enkephalins at the anti-emetic centre. Acupuncture techniques might also be promoting their anti-emetic effects by causing endogenous enkephalin release: an assessment of this would be interesting.
Until such time however, that each component of the emetic pathway is adequately analysed, it appears that the most effective anti-emetic regimens will be those combinations of drugs which block several of the identified pathways. It is therefore necessary that combination regimens are continued to be evaluated against single drugs and each other, so that major emetic control may be achieved in the greatest possible number of patients. 
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